Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib

2019 Genitourinary Cancers Symposium

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses phase III findings on a comparison of tivozanib and sorafenib in patients with refractory advanced renal cell carcinoma (Abstract 541).

Jason A. Efstathiou, MD, DPhil, on Bladder Cancer: What Is the Best Treatment Option?

Jason A. Efstathiou, MD, DPhil, of Massachusetts General Hospital, discusses the debate over treating muscle-invasive bladder cancer with radical cystectom...

Kidney Cancer

Ignacio Duran, MD, PhD, on Renal Cell Carcinoma: Results From the METEOR Trial on Cabozantinib vs Everolimus

Ignacio Duran, MD, PhD, of the Hospital Universitario Marqués de Valdecilla, discusses an overall survival analysis of the phase III METEOR trial of cabozantinib vs everolimu...

Kidney Cancer

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses current models used to estimate the risk of recurrence as well as genomic da...

Bladder Cancer

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Results From the RANGE Trial on Ramucirumab and Docetaxel

Thomas Powles, MD, PhD, of Queen Mary University of London, discusses phase III study findings on ramucirumab plus docetaxel vs placebo plus docetaxel in patients with advanc...

Prostate Cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial on Abiraterone Acetate Plus Prednisone

Karim Fizazi, MD, PhD, of the University of Paris-Sud and Gustave Roussy, discusses final phase III findings on men with newly diagnosed, high-risk, metastatic, castration-na...

Oct

Today In Oncology

Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib

Related Videos

Jason A. Efstathiou, MD, DPhil, on Bladder Cancer: What Is the Best Treatment Option?

Ignacio Duran, MD, PhD, on Renal Cell Carcinoma: Results From the METEOR Trial on Cabozantinib vs Everolimus

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Results From the RANGE Trial on Ramucirumab and Docetaxel

Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial on Abiraterone Acetate Plus Prednisone

FDA Approves Remdesivir for Patients With COVID-19 Requiring Hospitalization

FDA Pipeline Priority Reviews in EGFR-Mutant Lung Cancer, Advanced Renal Cell Carcinoma; Fast Track Designations in CLL and Solid Tumors

Addition of Atezolizumab to Neoadjuvant Chemotherapy in Early-Stage Triple-Negative Breast Cancer

First-Line Durvalumab With or Without Tremelimumab vs Chemotherapy for Metastatic Urothelial Carcinoma

Novel Small-Molecule Inhibitor Surufatinib for Advanced Extrapancreatic Neuroendocrine Tumors